34. (New) The conjugate of Claim 30 further characterized by the absence of noncovalent bonds.

35. (New) The conjugate of Claim 30 further characterized by conjugation of the peptide at least one terminus thereof.

36. (New) The conjugate of Claim 30 further characterized by conjugation of the peptide at least one N-terminus thereof

37. (New) The conjugate of Claim 30, wherein said water-soluble, nonpeptidic polymer is polyethylene glycol or a copolymer of polyethylene glycol and polypropylene glycol.

38. (New) The conjugate of Claim 30, wherein said water-soluble, nonpeptidic polymer is polyethylene glycol.

39. (New) The conjugate of Claim 38 wherein said polyethylene glycol is selected from the group consisting of monomethoxypolyethylene glycol, branched polyethylene glycol, polyethylene glycol with degradable linkages in the backbone, homobifunctional polyethylene glycol, heterobifunctional polyethylene glycol, multi-arm polyethylene glycol, pendant polyethylene glycol, and forked polyethylene glycol.

40. (New) The conjugate of Claim 30, wherein said peptide is conjugated to at least one polyethylene glycol molecule.

41. (New) The conjugate of Claim 30, wherein said biphalin has two polyethylene glycol moieties covalently attached.

42. (New) The conjugate of Claim 30 wherein said nonpeptidic polymer is polyethylene glycol having a nominal average molecular weight of about 200 daltons to about 100,000 daltons.

43. (New) The conjugate of Claim 42 wherein said polyethylene glycol has a nominal average molecular weight of about 1000 daltons to about 40,000 daltons.

44. (New) The conjugate of Claim 42, wherein said polyethylene glycol has a nominal average molecular weight of 2000 daltons.

45. (New) A pharmaceutical composition comprising a conjugate according to Claim 30 and a pharmaceutically acceptable carrier for said conjugate.

46. (New) The conjugate of Claim 30 further comprising a neuroactive agent, which may be the same or different from said peptide, conjugated to said non-peptidic polymer.

47. (New) The conjugate of Claim 30 further characterized by a dumbbell structure and further comprising a neuroactive agent, which may be the same or different from said peptide, conjugated to said nonpeptidic polymer.

48. (New) The conjugate of Claim 30 further comprising doxorubicin or an imaging agent conjugated to said nonpeptidic polymer.

49. (New) A substantially hydrophilic conjugate comprising an analgesic peptide covalently linked from solution to a water soluble, nonpeptidic polymer and wherein said conjugate is characterized by the absence of noncovalent bonds and can transport across the blood-brain barrier of a mammal, and said nonpeptidic polymer is characterized by the absence of lipophilic moieties, and wherein said peptide is selected from the group consisting of dynorphin A, enkephalins, double enkephalins, and endorphins.

50. (New) A substantially hydrophilic conjugate comprising an analgesic peptide covalently linked from solution to a water soluble, nonpeptidic polymer and wherein said conjugate is characterized by the absence of noncovalent bonds and can transport across the blood-brain barrier of a mammal, and said nonpeptidic polymer is characterized by the absence

of lipophilic moieties, and wherein said peptide is selected from the group consisting of biphalin and [D-Pen2, D-Pen5] enkephalin (DPDPE).